Cellular Immunology

Many biologic drugs (e.g. therapeutics for cancer treatment like engineered antibodies with enhanced effector function, immunocytokines, T cell binders and immune checkpoint modulators) are intended to modulate the immune system and therefore may affect the cell-mediated immunity.
IBR Inc. has 20 years of expertise in cell-based assays. We leverage this knowhow to offer a variety of assays to assess cellular immunology in-vitro. The services of IBR Inc. include assay development and validation as well as measurement of samples under GxP. In combination with the immunogenicity testing service, IBR Inc. provides comprehensive solutions for your immunotoxicity evaluations.

Our Cellular Immunology Service

Our Cellular Immunology Service includes but is not limited to:


Immunophenotyping and functional analysis of immune cells is a key expertise of IBR Inc. We perform assays with whole blood, PBMCs and isolated immune cell subsets to analyze intracellular and surface marker expression and immune cell function: apoptosis, phagocytosis and cytotoxicity, immune cell proliferation and cytokine quantification (multiplex BD™ Cytometric Bead Array, CBA). Our state-of-the-art Flow cytometers enable us to perform multi-panel and multicolor immunophenotyping and functional studies with the highest data reproducibility and in compliance with regulatory requirements.

For characterization of rare cell populations or for single cell analysis we offer Enzyme-linked immunospot (ELISpot) analysis.

The Fc-part of therapeutic Antibodies may elicit immunologic effector functions like Antibody Dependent Cellular Cytotoxicity (ADCC), Antibody Dependent Cellular Phagocytosis and Complement Dependent Cytotoxicity (CDC). IBR Inc. offers cell-based assays for evaluation of ADCC, ADCP and CDC. Furthermore, we provide cell-based or non cell-based binding assays for the Fcg Receptors CD16a, CD16b, CD32a, CD32b, CD64 and FcRn as well as C1q

The immune cell activation upon treatment with anti-cancer therapeutic agents including T-cell bispecific antibodies (TCBs), Antibody-Drug-Conjugates (ADCs), immunocytokines, checkpoint inhibitors, immunomodulators and antibodies with enhanced effector function can be assessed in-vitro on human whole blood, PBMCs or isolated immune cell subsets. For the evaluation of the immune cell function we are capable to use multiple readouts e.g. immune cell proliferation, target specific cell-death, cytokine measurement (intra-or extracellular), expression of activation/exhaustion markers and phenotypic characterization of lymphocyte subsets. We invite you to discuss your specific needs with us in order to provide you with a solution tailored to your needs.

IBR Inc. has capability to optimize culturing conditions, perform functional screening and product validation for CAR-T and NK CAR deriving from patients or from engineered CD34+ stem/progenitor cells or pluripotent stem cells for cellular immunotherapy. 

IBR Inc. interrogates 3D cellular models to study how immune cells tackle the challenge of infiltrating solid tumor mass, that can be mimicked by complex 3D spheroids composed of different cell types.

- read more

Submit a Question or Request

Simply fill out the form below and a member of our team will follow up with you shortly.


I accord my agreement for the usage and processing of my personal data for the purpose of processing my inquiry (see Privacy Policy). I am aware that I have the right to object the processing of my data at any time and with effect for the future.